CTRI/2013/12/004239Other未知
A double blind, placebo controlled study to evaluate the efficacy and safety of IBHB tablets in the management of urolithiasis
Indus Biotech Private Limited Pune0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Males or females aged 18 to 65 years, both inclusive.2) Symptomatic and asymptomatic cases with radiographic evidence (abdominal USG report up to two weeks prior to screening will be accepted) of diagnosis of renal calculi 3) In case of subjects with multiple calculi, at least one calculus must be 5 mm and all calculi should be 10 mm 4) Subjects willing to refrain from the use of any other herbal treatment for urolithiasis during the entire course of the study 5) Subjects willing to adopt a reliable and effective method of contraception during the course of the study such as abstinence, oral contraceptive pills, barrier method, etc 6) Subjects willing to provide a written informed consent
排除标准
- •1) Subjects with urinary tract infection 2) Subjects with obstructive uropathy 3) Subjects with known metabolic or endocrinal disorders favouring calculus formation 4) Subjects with known history of hypersensitivity to lactose 5) Subjects with malignancy 6) Subjects with poorly controlled diabetes as observed by a HbA1c of >10% 7) Subjects suffering from chronic systemic illnesses like rheumatoid arthritis,psychoneural-endocrinal disorders, etc necessitating long term therapy 8) Subjects with a history of atrial fibrillation, coronary artery disease, acute coronary syndrome,myocardial infarction, stroke or severe arrhythmia in the past 6 months 9) Subjects with poorly controlled hypertension, as observed by a blood pressure (BP) reading of >160/100 mm Hg in the supine position 10) Subjects on prolonged treatment with corticosteroids, antidepressants, anticholinergics, etc or any other medication that may have an influence on the outcome of the study. Subjects should not have consumed any of these for at least six weeks prior to screening 11) Subjects with severe hepatic disorder, defined as AST, ALT, total bilirubin, and ALP levels >2 times ULN or renal disorder, defined as serum creatinine levels >1.2 mg/dL 12) Subjects with severe pulmonary dysfunction such as uncontrolled bronchial asthma and/or chronic obstructive pulmonary disease, inflammatory bowel disease, or any other condition which could influence the outcome of the study 13) Subjects who are currently dependent on or abusing, alcohol or one or more of the following: cannabis, cocaine, hallucinogens, inhalants, opioids, sedatives or hypnotics 14) Subjects with known hypersensitivity to the investigational product or its ingredients 15) Subjects with a history of food allergy 16) Subjects with known allergy to diclofenac sodium 17) Subjects who have participated in any other investigational study in the past 6 months 18) Subjects with known HIV, Hepatitis B or Hepatitis C infections 19) Subjects with a positive pregnancy test at screening or who is a lactating female 20) Subjects with any medical condition that in the investigatorâ??s opinion may threaten the subjectâ??s ability to complete the study
研究者
相似试验
进行中（未招募）
1 期
A double blind, placebo controlled study to evaluate the safety and immunogenicity of escalating doses of 108 CFU, 109 CFU and 1010 CFU of M04NM11 in patients who have chronic Hepatitis B infection. - Not AvailableChronic hepatitis B virus infectionEUCTR2005-005293-70-GBEmergent Product Development UK Ltd45
已完成
不适用
A double blind, placebo controlled study to evaluate the safety and immunogenicity of escalating doses of 10^8 colony forming units (CFU), 10^9 CFU and 10^10 CFU of M04NM11 in patients who have chronic hepatitis B infectioChronic viral hepatitisChronic hepatitis B virusInfections and InfestationsISRCTN96199656Emergent Product Development UK Ltd (UK)45
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001760-19-NLTheracos Sub, LLC1,650
已完成
3 期
A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse eventsType 2 diabetes and increased risk of cardiovascular adverse events100192801001842410003216NL-OMON47856Theracos Sub, LLC132
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861EUCTR2015-001760-19-DKTheracos Sub, LLC1,650